Hypertrophic cardiomyopathy (HC), affecting approximately 0.2% to 0.5% of global adult population, is often associated by loss-of-function mutations in myosin binding protein C3 (MYBPC3) (37). This evidence concerns the gene MYBPC3 and hypertrophic cardiomyopathy.